During the period 18 August 2022 – 1 September 2022, holders of warrants of series TO 1 have been entitled to subscribe for shares with warrants. A total of 1,065,335 warrants of series TO 1 were exercised, corresponding to an exercise rate of approx. 92 percent. CS MEDICA will receive approx. DKK 9.9 million before deduction of transaction related costs of approx. DKK 0.8 million.

Lone Henriksen, CEO CS MEDICA comments
“We are very pleased with the successful warrant exercise. We welcome all new and existing shareholders on our continued journey ahead”.

Number of shares and share capital
In total, 1,065,335 warrants of series TO 1 have been exercised, corresponding to a subscription rate of approx. 92 percent. Through the warrants of series TO 1, the Company will thus receive approx. DKK 9.9 million before issue costs, which are estimated to amount to approx. DKK 0.8 million (approx. 8 percent of the net proceeds in the Company’s exercise of warrants). When the new shares have been registered with the Danish Companies Registration Office, the number of shares in CS MEDICA will increase from 11,257,300 shares to 12,322,635 shares and the share capital will increase from DKK 731,724.50 to DKK 800,971.275. The planned conversion date from interim shares to common shares is expected to take place around mid-September 2022, and the common shares are expected to be visible in each subscriber’s account two days after the conversion.

For further information regarding the exercise of warrants, please contact:
Sedermera Corporate Finance AB
Phone: +46 40 – 615 14 10
E-mail: cf@sedermera.se
www.sedermera.se

Nordic Issuing AB
Phone: +46 (0)40 – 632 00 20
E-mail: info@nordic-issuing.se
www.nordic-issuing.se

This disclosure contains information that CS MEDICA A/S is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 06-09-2022 08:45 CET.

For more information about CS MEDICA, please contact:
Lone Henriksen, CEO
Phone: + (45) 71 20 30 47
Email: lh@cs-medica.com
Website: https://www.cs-medica.com/

CS MEDICA A/S is a Danish medico cannabis company founded in 2011. CS MEDICA is committed to developing, manufacturing, and commercializing over-the-counter (OTC) medical device products containing cannabinoids. The Company runs its business through the two fully-owned subsidiaries, Galaxa Pharma A/S (distributor and representative of foreign manufacturers in the Nordic, registered medical device product distributor) and CanNordic A/S (Medical device developer and seller (BtB), registered medical device product manufacturer). CS MEDICA distributes products across the European borders and is headquartered in Copenhagen, Denmark.

The company is listed on Spotlight Stock Market in Stockholm (symbol: “CSMED”). For more information about CS MEDICA cs-medica.com.

Tags: